Founder, President and CEO

Chief Financial Officer

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Nuvation Bio to report third quarter 2025 financial results and provide business update on November 3, 2025

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Why Nuvation Bio Stock Is Skyrocketing Today

Associate Director, Regulatory Affairs

Nuvation Bio is a biopharmaceutical company focused on developing novel therapeutic candidates for oncology. The Associate Director of Regulatory Affairs will lead regulatory submissions and collaborate with cross-functional teams to advance clinical and commercial stage programs.

Associate Director, Regulatory Affairs - Contract

VP, Total Rewards and People Operations

Vice President, Legal

Chief Regulatory Officer

Chief Scientific Officer

Associate Director of CMC Regulatory Affairs

Sign up with Google

Sign in with Google